Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2020.11.017
Abstract: BACKGROUND & AIMS Data on patients with chronic hepatitis C virus (HCV) infection who failed voxilaprevir (VOX), velpatasvir (VEL), sofosbuvir (SOF) retreatment and rescue treatment options for these patients are limited. METHODS Samples of 40… read more here.
Keywords: vel; vel sof; treatment; vox vel ... See more keywords
Spectrophotometric and robust UPLC methods for simultaneous determination of velpatasvir and sofosbuvir in their tablet
Sign Up to like & getrecommendations! Published in 2019 at "Microchemical Journal"
DOI: 10.1016/j.microc.2019.103996
Abstract: Abstract Three new methods were developed for the simultaneous determination of velpatasvir (VEL) and sofosbuvir (SOF) in bulk powder and in their pharmaceutical dosage form. Two spectrophotometric methods included first derivative of ratio spectra (1DD)… read more here.
Keywords: simultaneous determination; determination velpatasvir; vel; sof ... See more keywords
Cas d’allo-immunisation anti-Vel : identification sérologique et confirmation par génotypage
Sign Up to like & getrecommendations! Published in 2019 at "Transfusion Clinique et Biologique"
DOI: 10.1016/j.tracli.2019.06.081
Abstract: Le systeme Vel comprend un seul antigene de grande frequence : l’antigene Vel exprime chez plus de 99,9 % de la population. Le phenotype VEL :-1 est exceptionnel, le principal mecanisme moleculaire aboutissant a ce phenotype est une deletion… read more here.
Keywords: anti vel; cas allo; phenotype; par ... See more keywords
Characterization of patients with BRCA mutated ovarian cancer who are eligible versus not eligible for PARP inhibitor maintenance therapy: exploratory analysis of the VELIA study
Sign Up to like & getrecommendations! Published in 2021 at "Gynecologic Oncology"
DOI: 10.1016/s0090-8258(21)00846-5
Abstract: Objectives: Previous phase 3 trials of front-line maintenance with the PARP inhibitors (PARPi) olaparib and niraparib only included patients (pts) with complete (CR) or partial (PR) response following front-line chemotherapy (CT); both agents were adopted… read more here.
Keywords: vel; maintenance; therapy; mne ... See more keywords
Oxygen abundance of γ Vel from [O iii] 88μm Herschel/PACS spectroscopy
Sign Up to like & getrecommendations! Published in 2024 at "Monthly Notices of the Royal Astronomical Society"
DOI: 10.1093/mnras/stae145
Abstract: We present Herschel PACS spectroscopy of the [O iii] 88.4μm fine-structure line in the nearby WC8+O binary system γ Vel to determine its oxygen abundance. The critical density of this line corresponds to several 105R* such… read more here.
Keywords: abundance; spectroscopy; vel; herschel pacs ... See more keywords
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13549
Abstract: Sustained viral response (SVR) rates for direct‐acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection routinely exceed 95%. However, a small number of patients require retreatment. Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is a potent… read more here.
Keywords: vel; retreatment; sof vel; daa ... See more keywords
The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13814
Abstract: To evaluate the safety and tolerability of the fixed‐dose, single‐tablet regimen sofosbuvir/velpatasvir (SOF/VEL) for the treatment of hepatitis C virus (HCV) infection in three Phase 3 studies in patients with and without compensated cirrhosis. Data… read more here.
Keywords: safety; sof vel; tolerability; patients treated ... See more keywords
Abstract 7181: Gene enhancers as novel rationale therapeutic targets for impeding colorectal cancer progression
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-7181
Abstract: Half of of colorectal cancer (CRC) patients develop metastatic CRC (mCRC) with a low survival rate. Epigenetic abnormalities in promoters and enhancers play a significant role in CRC advancement and hold promise for diagnosis and… read more here.
Keywords: colorectal cancer; vel; cancer; therapeutic targets ... See more keywords
A phase I study of veliparib (Vel) in combination with oxaliplatin (Ox) and capecitabine (Cap) in advanced solid tumors.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.314
Abstract: 314Background: Poly(ADP-ribose) polymerases (PARP) are activated by DNA strand breaks and important for DNA repair in response to platinum-based chemotherapy. PARP inhibition with Vel might enhance anti-tumor effects of Cap with Ox. This phase I… read more here.
Keywords: combination; vel; study veliparib; phase study ... See more keywords
Female urine incontinence: vaginal erbium laser (VEL) effectiveness and safety
Sign Up to like & getrecommendations! Published in 2020 at "Hormone Molecular Biology and Clinical Investigation"
DOI: 10.1515/hmbci-2020-0012
Abstract: Abstract Urinary incontinence is a common health problem that impacts the quality of life of women at different ages. Its physiopathology is not unequivocal, and it is necessary to consider the stress urinary incontinence (SUI),… read more here.
Keywords: effectiveness safety; vel; laser; incontinence ... See more keywords
[The changes in the pharmacotherapy of heart failure with reduced ejection fraction and its effect on prognosis: experience in the Hungarian clinical practice].
Sign Up to like & getrecommendations! Published in 2024 at "Orvosi hetilap"
DOI: 10.1556/650.2024.33045
Abstract: Bevezetés: Az ESC 2021-es Szívelégtelenség Irányelve egyértelmű útmutatást ad a csökkent ejekciós frakciójú szívelégtelenség gyógyszeres kezelésére. A konvencionális neurohormonális antagonista hármas terápia (TT) (RASi + βB + MRA) a legújabb vizsgálatok eredményei alapján a minden… read more here.
Keywords: vel gtelens; vel; kkent ejekci; alkalmaz ... See more keywords